@article{oai:nagasaki-u.repo.nii.ac.jp:00009338,
 author = {Mizuta, Shuichi and Matsuo, Keitaro and Maeda, Tomoya and Yujiri, Toshiaki and Hatta, Yoshihiro and Kimura, Yukihiko and Ueda, Yasunori and Kanamori, Heiwa and Usui, Noriko and Akiyama, Hideki and Takada, Satoru and Yokota, Akira and Takatsuka, Yoshifusa and Tamaki, Sigehisa and Imai, Kiyotoshi and Moriuchi, Yukiyoshi and Miyazaki, Yasushi and Ohtake, Shigeki and Ohnishi, Kazunori and Naoe, Tomoki},
 issue = {5},
 journal = {Blood Cancer Journal},
 month = {Jun},
 note = {We investigated prognostic factors for the clinical outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) following imatinib-based therapy. Among 100 adult patients who were prospectively enrolled in the JALSG Ph+ALL202 study, 97 patients obtained complete remission (CR) by imatinib-combined chemotherapy, among whom 60 underwent allo-HSCT in their first CR. The probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years after HSCT were 64% (95% CI, 49–76) and 58% (95% CI, 43–70), respectively. Prognostic factor analysis revealed that the major BCR–ABL transcript was the only unfavorable predictor for OS and DFS after HSCT by both univariate (HR, 3.67 (95% CI 1.49–9.08); P=0.005 and HR, 6.25 (95% CI, 1.88–20.8); P=0.003, respectively) and multivariate analyses (HR, 3.20 (95% CI, 1.21–8.50); P=0.019 and HR, 6.92 (95% CI, 2.09–22.9); P=0.002, respectively). Minimal residual disease status at the time of HSCT had a significant influence on relapse rate (P=0.015). Further study of the BCR–ABL subtype for the clinical impact on outcome of allo-HSCT in Ph+ALL is warranted., Blood Cancer Journal, 2(5), e72; 2012},
 title = {Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL},
 volume = {2},
 year = {2012}
}